PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT6183163

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date	
JASON J. MARINEAU	06/25/2020	
MICHAEL BRADLEY	06/25/2020	
CLAUDIO EDMUNDO CHUAQUI	06/25/2020	

RECEIVING PARTY DATA

Name:	SYROS PHARMACEUTICALS, INC.
Street Address:	35 CAMBRIDGEPARK DRIVE
City:	CAMBRIDGE
State/Country:	MASSACHUSETTS
Postal Code:	02140

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	16787753

CORRESPONDENCE DATA

Fax Number: (617)523-1231

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: (617) 570-8764

Email:us-patentbos@goodwinlaw.comCorrespondent Name:GOODWIN PROCTER LLPAddress Line 1:100 NORTHERN AVENUEAddress Line 2:IP DOCKETING DEPT./7TH FL

Address Line 4: BOSTON, MASSACHUSETTS 02210

ATTORNEY DOCKET NUMBER:	SYR-037
NAME OF SUBMITTER:	DEREK DENHART
SIGNATURE:	/Derek Denhart/
DATE SIGNED:	07/02/2020

Total Attachments: 2

source=Assignment Executed by Marineau, Bradley, and Chuaqui to Syros Pharmaceuticals, Inc. with Countersignature#page1.tif

source=Assignment Executed by Marineau, Bradley, and Chuaqui to Syros Pharmaceuticals, Inc. with

PATENT REEL: 053108 FRAME: 0544

506136436

Countersignature#page2.tif

PATENT REEL: 053108 FRAME: 0545

Attorney Docket No.: SYR-037 Syros Reference No.: SYRS-027001

ASSIGNMENT BY INVENTORS

For good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, I, Jason J. Marineau of 2 Mackintosh Street, Franklin, MA, 02038 (USA); I, Michael Bradley, of 338 W. 21st Street, Houston, TX, 77008 (USA); and I, Claudio Edmundo Chuaqui of 83 Menotomy Road, Arlington, MA, 02476 (USA) (collectively the "Assignors"), have made an invention described in the non-provisional patent application entitled "Inhibitors of Cyclin-Dependent Kinase 7 (CDK7)" (the "Invention(s)"), which was filed on February 11, 2020, with the United States Patent and Trademark Office and assigned Application No. 16/787,753 ("the Patent Application"), and I have sold, assigned and transferred by an agreement duly entered into and by these presents do hereby sell, assign and transfer my entire right, title and interest throughout the world in and to the Invention(s) and the Patent Application to Syros Pharmaceuticals, Inc., a Delaware corporation having its principal place of business at 35 CambridgePark Drive, Cambridge, Massachusetts 02140 (herein "Assignee"), its successors and assigns ("Assignment").

This Assignment encompasses the Invention(s) and the Patent Application as well as any patent application that claims the benefit of the priority date of the Patent Application under United States law or international convention and the invention(s) described therein, such applications including, but not limited to, any application filed under the Patent Cooperation Treaty (a "PCT Application"), any application entering the national phase from the Patent Application or a PCT Application, any utility application or continuation thereof, including any continuation-in-part or divisional application, any patent application or patent issuing thereon subjected to a reinstatement, renewal, reissue or reexamination process, any patent application or patent issued thereon deemed an extension or substitution of the Patent Application or any of the foregoing applications, and any patent, including any Letters Patent, that issues from any of the foregoing applications or claims or has the right to claim priority thereto. This Assignment conveys to Assignee, its successors and assigns, the full right to claim all benefits and priority rights under any applicable law, convention, or treaty, including the right to sue for injunctive relief or damages caused by past infringement or any other cause of action accruing prior to this Assignment. The inventions, patent applications and patents referenced herein are to be held and enjoyed by the Assignee for its own use and behalf and for its successors and assigns until the full end of the term(s) for which any patent(s) may be granted as fully and entirely as if the same would have been held by me had this Assignment not been made.

I hereby acknowledge that this Assignment carries with it the right by Assignee to apply for and obtain from competent authorities in all countries of the world any and all Letters Patent by attorneys and agents of Assignee's selection and the right to procure the grant of all Letters Patent to Assignee in its own name. I hereby authorize and request the Director of the United States Patent and Trademark Office and the empowered officials of all other governments to issue Letters Patent as described herein upon the Patent Application or any application(s) based thereon, to the Assignee, its successors, or assigns.

I hereby agree, when requested, and without further consideration, to execute all oaths, assignments, powers of attorney, declarations, and any other papers necessary or desirable to fully secure to the Assignee the rights, titles and interests conveyed by this Assignment and to fully communicate to the Assignee all known facts relating to the Invention(s). I further agree to assist the Assignee by providing statements or testimony in any proceeding in which the Invention(s) may be involved, for consideration to be negotiated as need be and in good faith.

1

Attorney Docket No.: SYR-037 Syros Reference No.: SYRS-027001

I represent that I have not made and will not make any assignment, grant, mortgage, license or other agreement that conflicts with the terms and covenants of this Assignment.

The terms and covenants of this Assignment shall inure to the benefit of the Assignee, its successor or assigns and shall be binding upon the Assignors and their respective heirs, legal representatives and assigns.

IN WITNESS WHEREOF, the Assignors have executed this Assignment.

<u>Assignors</u>		
Jason J. Marineau	Date: 6/25/2	
Michael Bradley Michael Bradley	Date:6/25/2	2020
Claudio Edmundo Chuaqui	Date:6/25/	2020

Accepted by Assignee's Authorized Representative:

Signature:

Representative's Name:

Gerald E. Quirk

Representative's Chief Legal & Administrative Officer & Corporate Secretary

Date:

Docusigned by:

Gerald E. Quirk

Chief Legal & Administrative

Officer & Corporate Secretary

RECORDED: 07/02/2020

2